ArticleBMC women's health2026
Disease characteristics, treatment, and overall survival outcomes of patients with locally advanced cervical cancer referred for radiation therapy in Johannesburg, South Africa: a 2-year retrospective study.
Article in BMC women's health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
purposeWe assessed the association between baseline patient characteristics, disease stage, and treatment-related factors and overall survival among women with locally advanced, non-metastatic cervical cancer in South Africa. PATIENTS AND
methodsWe retrospectively analysed data from 642 women with 2018 International Federation of Gynaecology and Obstetrics (FIGO) stage IB3-IVA cervical cancer who were referred for and deemed eligible for radiotherapy at a public tertiary hospital in South Africa between January 2021 and December 2022. All women discussed at the multidisciplinary team (MDT) meeting were included, irrespective of whether treatment was ultimately initiated. Demographic and clinical characteristics, treatment timelines, and survival outcomes were assessed. Multivariable Cox proportional‑hazards models were used to identify factors associated with overall survival.
resultsOf the 642 women, 54.1% were aged < 50 years and 60.3% were living with HIV. The stage distribution was: IB3, 1.7%; II, 43.5%; III, 50.1%; and IVA, 4.7%. The median time to treatment initiation was ~4 months; the median overall treatment duration was 63 days. The 2-year overall survival rate was 57.2% and varied by stage (IB3 and II, 70.0%; III, 49.3%; IVA, 12.4%; p < 0.001). On multivariable Cox regression analysis, worse survival was independently associated with Eastern Cooperative Oncology Group performance status 2-4 [vs. 0 and 1; adjusted hazard ratio (aHR), 1.75], stage III (vs. IB3 and II; aHR, 1.46) stage IVA (vs. IB3 and II; aHR, 2.02), and receipt of radiotherapy alone (vs. chemoradiation; aHR, 1.96). A significant interaction between EQD2 and overall treatment duration was observed. Patients receiving EQD2 <80 with treatment duration <56 days was associated with worse overall survival (aHR 2.65). HIV status was not associated significantly with survival.
conclusionsOverall Survival in women with locally advanced cervical cancer in South Africa was associated with disease stage, baseline patient characteristics, and treatment-related factors. Interventions targeting timely delivery of standard of care may improve survival in this setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.